Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360149 | 0.87 | KDM4E (0.35) | DGAT1ALDH1A1POLBTSHRSRC | |
| SCHEMBL29287973 | 0.85 | DGAT1 (0.32) | DGAT1ALDH1A1POLBSRC | |
| SCHEMBL2405243 | 0.79 | MEN1 (0.44) | USP2LMNAGAA | |
| SCHEMBL27375665 | 0.79 | GAA (0.46) | ALDH1A1USP2LMNAGAAMGAM | |
| SCHEMBL1902123 | 0.78 | — | — | |
| SCHEMBL28157759 | 0.78 | DGAT1 (0.37) | DGAT1ALDH1A1POLBTSHRSRC | |
| SCHEMBL809243 | 0.77 | DGAT1 (0.40) | DGAT1ALDH1A1POLBTSHRSRC | |
| SCHEMBL16705046 | 0.76 | DGAT1 (0.41) | DGAT1ALDH1A1POLBTSHRKCNN4 | |
| SCHEMBL3430619 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNAGAAMGAM | |
| SCHEMBL28869957 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240392329-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSES | BRASKEM S.A. (BR) | 2024-11-28 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12006526-B2 | Microorganisms and methods for the production of oxygenated compounds from hexoses | BRASKEM S.A. (BR) | 2024-06-11 | — | — | US | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11584944-B2 | Degradation pathway for pentose and hexose sugars | BRASKEM S.A. (BR) | 2023-02-21 | — | — | US | disclosed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006099735-A1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK FROSST CANADA LTD. (CA) | 2006-09-28 | — | — | WO | disclosed |
| EP-0382276-B1 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | ACRAF (IT) | 1995-08-30 | — | — | EP | disclosed |
| US-5112986-A | Chemical intermediates for analgesics | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1992-05-12 | — | — | US | disclosed |
| US-4999367-A | Analgesics | AZIENDE CHIMICHE RUINITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 1991-03-12 | — | — | US | disclosed |
| EP-0382276-A2 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
| US-4774253-A | ETHER,-ACIDS, ESTERS OR AMIDES | HOFFMANN-LA ROCHE INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4208423-A | Anticholinergic bronchodilators | SYNTEX INC. (US) | 1980-06-17 | — | — | US | disclosed |
| EP-0012071-A1 | Azoniaspiro derivatives, process for their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | DGAT1 1234/4885ALDH1A1 811/4885POLB 2514/4885 |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | DGAT1 2707/4885ALDH1A1 665/4885POLB 2029/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | DGAT1 1234/4885ALDH1A1 811/4885POLB 2514/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | DGAT1 1314/4885ALDH1A1 633/4885POLB 3388/4885 |
| US-20070149579-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | DGAT1 569/4885ALDH1A1 431/4885POLB 3997/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | DGAT1 1234/4885ALDH1A1 811/4885POLB 2514/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | DGAT1 4152/4885ALDH1A1 559/4885POLB 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.